HUAWEI
2.3.2023 15:59:42 CET | Business Wire | Press release
During MWC23 in Barcelona, Huawei and leading Saudi Arabian telecommunications operator Zain KSA signed a strategic cooperation Memorandum of Understanding (MoU) for "5.5G City" joint innovation project. The MoU was signed during MWC23 held in Barcelona from February 27 to March 2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005600/en/
MoU signing between Zain KSA and Huawei in Barcelona
Under the MoU, both parties will work together to promote technological innovation for 5.5G evolution and expand scalable offerings to individual, enterprise, and government customers. Additionally, they will strengthen the digital infrastructure and build a global 5.5G evolution pioneer network, providing a strong engine to achieve the national digitalization goals outlined in Saudi Vision 2030.
Zain KSA and Huawei will collaborate to enhance technological innovation, improve user experience, and develop new use cases. The collaboration will involve providing a seamless gigabit experience in both indoor and outdoor scenarios through the large-scale deployment of MetaAAU and 5G carrier aggregation, as well as LampSite digital indoor solutions. Additionally, initiatives will be taken to enhance the performance of Massive MIMO networks and to develop end-to-end autonomous network operation and optimization capabilities. Both parties will also work together to develop new use cases for the Internet of Things (IoT) and private network solutions. Finally, the partnership will explore innovative cooperation in areas such as ultra-compact site and green energy solutions, among others.
Zain KSA's Chief Technology Officer, Eng. Abdulrahman Al-Mufadda, commented: "Our commitment to driving digital transformation in the Kingdom has been made possible by combining innovative technology investments with pioneering digital solutions across multiple fields, including cloud computing, fintech, business support, and drone technologies. Zain KSA is on a mission to empower a digital society and support the transition towards a digital economy, in line with Saudi Vision 2030 and the Kingdom's digital transformation strategy. By partnering with global ICT leaders, including Huawei, we are committed to enhancing Zain KSA's end-to-end network through our joint innovation on 5G-Advanced technology and by incubating a range of vertical services for industry digitalization."
Ritchie Peng, President of Huawei's 5G Product Line, said, "We are committed to providing leading products and solutions for operators and helping them build high-quality mobile networks through continuous technical innovations. We are excited to work with Zain KSA on this 5.5G City project and hope that this cooperation will allow our innovative products and solutions to create business and social value. Our vision is to help Zain KSA build better 5G networks and more importantly, leading digital infrastructure."
MWC Barcelona 2023 runs from February 27 to March 2 in Barcelona, Spain. Huawei showcases its products and solutions at stand 1H50 in Fira Gran Via Hall 1. Together with global operators, industry professionals, and opinion leaders, we dive into topics such as 5G business success, 5.5G opportunities, green development, digital transformation, and our vision of using the GUIDE business blueprint to lay the foundation for 5.5G and build on the success of 5G for even greater prosperity. For more information, please visit: https://carrier.huawei.com/en/events/mwc2023.
About Zain KSA
Zain KSA is a leading telecom provider established in the Kingdom of Saudi Arabia on August 2008 as a listed company. In due respect to its highly developed infrastructure, the company was successful in establishing itself as a reliable telecom operator and a digital service provider whose services include telecom services, 5G network, digital payment services, cloud computing, IoT solutions, fiber services, drones, and many others.
Zain KSA is committed to the continuous development of its network and services in order to achieve the best customer service experience for individuals, the private sector and government institutions, in line with the goals of Saudi Vision 2030 and the digital transformation in the Kingdom of Saudi Arabia which is to provide the services needed for a smart society and a better quality of life.
For more information on Zain KSA please visit: www.sa.zain.com.
About Huawei
Founded in 1987, Huawei is a leading global provider of information and communications technology (ICT) infrastructure and smart devices. We have 197,000 employees and we operate in more than 170 countries and regions, serving more than three billion people around the world.
Our vision and mission is to bring digital to every person, home and organization for a fully connected, intelligent world. To this end, we will work towards ubiquitous connectivity and inclusive network access, laying the foundations for an intelligent world; bring cloud and intelligence to all four corners of the earth to provide diversified computing power where you need it, when you need it; build digital platforms to help all industries and organizations become more agile, efficient, and dynamic; and redefine user experience with AI, making it smarter and more personalized for people in all aspects of their life, whether they're at home, on the go, in the office, having fun, or working out. For more information, please visit Huawei online at www.huawei.com or follow us on:
http://www.linkedin.com/company/Huawei
http://www.twitter.com/Huawei
http://www.facebook.com/Huawei
http://www.youtube.com/Huawei
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005600/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom